AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: Genentech / Evrysdi (evrysdi.com)
This is a low-BS, highly regulated medical site where substance is mandated by law. It successfully balances patient-centric messaging with rigorous clinical data, avoiding the generic ‘breakthrough’ traps of less mature biotech startups.
To further reduce the score, replace conceptual headings like ‘Some things get everywhere’ with more descriptive clinical benefits in the H1. Ensure that all patient ambassador quotes are directly linked to the specific clinical trial data that mirrors their experience. Add ClinicalTrials.gov registration numbers directly to the ‘How it was studied’ section to provide a direct proof path to raw data.
The site maintains high information density, particularly in technical sections. While headings like ‘Some things get everywhere’ and ‘Designed to be different’ use conceptual power words, they are immediately supported by specific substance, such as the claim that SMN protein levels in the blood ‘approximately doubled’ within 4 weeks. Specific numbers like ‘18,500+ people globally’ and the inclusion of patients ‘up to 75 years of age’ provide concrete anchors that offset marketing fluff.
When edges drift or clusters collapse, your content becomes a set of disconnected islands. Inspect your internal link topology to identify where authority flow breaks or never forms.
Semantic drift is minimal. The homepage H1 ‘Some things get everywhere’ serves as a metaphor for systemic treatment, which the ‘How Evrysdi Works’ page explicitly validates by listing target areas like the brain, spinal cord, larynx, and GI system. The promise of ‘Navigating your SMA journey’ is functionally supported by the Resources sub-page which provides direct contact info for Partnership and Access Liaisons (PALs) and financial assistance details.
Stop the ROI leak caused by technical debt and strategic misalignment. Conduct an Independent Strategic Diagnosis for 1 Euro to identify high impact issues across all audit categories.
The site avoids trust theatre entirely; its review_count is 0, which is appropriate for a regulated prescription medication where consumer reviews are often restricted. Instead of unverified testimonials, the site utilizes ‘Important Safety Information’ blocks and links to ‘Full Prescribing Information,’ providing a high level of verified regulatory proof rather than theatrical social proof.
The proof density is high, with a proof_links_count of 2 per page specifically pointing to technical prescribing documents. Specific clinical trial metrics (2 years of maintained results across SMA types) outnumber vague assertions, creating a site that is functionally a digital label and patient support portal rather than a sales pitch.
To see how the system reconstructs a medical entity graph at scale, review the full Cleveland Clinic Structured Data audit. View the Cleveland Clinic Structured Data Audit for a live example of identity level decomposition and cross page entity mapping.
The site uses several industry cliches such as ‘here for you’ and ‘make a difference,’ and the ‘Frequently Asked Questions’ and ‘Patient Resources’ follow standard pharmaceutical web templates. However, the value proposition is highly differentiated and drug-specific, centered on its unique status as an ‘oral, non-invasive’ treatment for SMA, preventing it from being interchangeable with competitors.
Authority is well-established through Genentech’s corporate identity and the drug’s FDA-approved status. While the site features patient ambassadors like ‘Jose,’ it relies more on institutional authority and regulatory compliance than named individual ‘gurus,’ which is consistent with high-substance biotech models. The schema_json includes detailed Organization and MedicalWebPage data, leaving no significant identity gaps.
There is no significant disconnect between claims and evidence. Performance claims regarding motor function preservation are clearly footnoted with the caveat ‘This was observed when Evrysdi was studied in animals’ where applicable, and clinical results are supported by line graphs and data exploration links rather than vague marketing assertions.
Medical Devices, Pharma & Biotech BS: Genentech / Evrysdi (evrysdi.com)
The site perfectly aligns with the Pharma & Biotech category. It adheres to strict regulatory communication standards, providing clear indications for use, safety information, and clinical trial results for the drug risdiplam.
A page that loads perfectly for users can still return an empty shell to an AI crawler. Examine the Crawlability Technical Guide and understand why script free extraction is the real measure of visibility.
“The score of 24 is driven primarily by the high Information Density and Trust and Proof pillars. The presence of actual clinical data, patient counts, and mandatory safety disclosures effectively neutralizes the minor penalties earned for conceptual marketing headings and template structures.”
Analysis Disclosure & Source Attribution
Snapshot Date: May 30, 2026
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to see how machine logic interprets digital signals.
Machine Perception Notice: This evaluation is generated by machine-read logic (MRL). The AI interprets the “Digital Ghost” of a website (code, metadata, and semantic structures), which may differ from what a human sees at the same moment. This is an automated technical diagnostic and not a statement of fact or human opinion regarding the real-world integrity or legitimacy of the business. Any missing or inaccessible elements in the snapshot are treated as machine-read signals, reflecting AI rendering limitations rather than intentional omission.
Notice to the Evaluated Business: This analysis is part of a non-adversarial audit. The results are intended as professional feedback to help improve machine-readability and authority signals. Any company can use these insights for free. When content is updated, a fresh audit can be requested at any time to reflect the current state.
To All Users: You are encouraged to visit the live site at Genentech / Evrysdi to view the most current version of their content and see directly what the company offers.